August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE)--Aug. 8, 2022-- Karuna Therapeutics , Inc.

Insights into GPCR Function Time-resolved cryo-EM of G-protein activation by a GPCR Industry News Domain Therapeutics Complex Protein Structures Newly discovered adhesion GPCR mayo controls midgut development in Drosophila Karuna Therapeutics announces that is now part of Bristol Myers Squibb GPCR Events, Meetings, and Webinars

July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON-- Tectonic Therapeutic , Inc. a pre-clinical

< GPCR News < GPCRs in Oncology and Immunology Noval insights and therapeutic strategies for tumor-induced receptor (TACR3), a homolog of the G protein-coupled receptor TkR99D in fruit flies, as a potential therapeutic The implications of these findings for transforming the therapeutic approaches to renal complications These insights could contribute to the advancement of diagnostic and therapeutic strategies for treating

< GPCR News < GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases

Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and